Study of Antrix Probiotics to Reduce Recurrent Respiratory Infections in Children Under 6 Years

What this Trial Is About

Recurrent respiratory tract infection RRTI is a common condition in children under six years old that affects their growth, development, and quality of life. This trial evaluates the clinical effects of Antrrix probiotics on children diagnosed with RRTI. The study aims to understand how probiotics might help improve respiratory symptoms and overall health by restoring gut microbiota balance and enhancing immune function. Participants are randomly assigned to receive either a daily dose of probiotic containing Lactobacillus rhamnosus CRL1505 and Bifidobacterium brevis M-16V strains in MCT oil or a placebo of MCT oil without probiotics. The treatment lasts for 8 weeks. Stool samples are collected before, during, and after treatment to analyze changes in gut bacteria through gene sequencing. During the study, researchers monitor respiratory symptoms and quality of life using questionnaires at multiple time points day 1, day 7, day 14, week 4, and week 8. They also assess immune biomarkers and gut microbiota profiles. The total participation period includes these assessments and sample collections to evaluate the probiotics impact and safety in young children with RRTI.

Evaluation of the Clinical Efficacy of Antrrix Probiotics in Improving Recurrent Respiratory Infections in Infants and Young Children